

# NATURE REVIEW

REVIEWS AND COMMENT FROM THE NATURE PUBLISHING GROUP



▲ **Oceans of bacteria** Stephen Giovannoni *Nature* 29 July (2004) The debate on what constitutes a bacterial species rumbles on. In this News and Views article, Stephen Giovannoni comments on work by Acinas and colleagues in which they analysed microbial diversity using 16S rRNA clone libraries from a marine bacterioplankton community and identified microdiverse clusters — populations of cells they suggest can be regarded as species or species 'ecotypes'.



▲ **Mutual attraction: does it benefit the host or the bug?**

JoAnne L. Flynn

*Nature Immunology* August (2004)

JoAnne Flynn discusses the implication of the work by Cosma *et al.* in which a *Mycobacterium marinum* model was used to analyse the dynamic nature of mycobacterial granulomas.

● **Antiprion immunotherapy: to suppress or to stimulate?**

Adriano Aguzzi &

Christina J. Sigurdson

*Nature Reviews Immunology*

September (2004)

Although human prion diseases are rare, they are invariably fatal, and treatments for them remain elusive. Aguzzi and Sigurdson review the pathophysiology of prion diseases in mouse models, and discuss their relevance to immunotherapeutic and immunoprophylactic antiprion strategies.

● **Working with dangerous bugs**

Helen Quill & Maria Giovanni

*Nature Immunology* August (2004)

● **Oncogenic mechanisms of**

*Helicobacter pylori* CagA protein

Masanori Hatakeyama

*Nature Reviews Cancer*

September (2004)

● **Staphylococcal protein A inflames the lungs**

Birgitta Henriques Normark, Staffan

Normark & Anna Norrby-Teglund

*Nature Medicine* August (2004)

● **Urgently needed: a filter for the HIV-1 vaccine pipeline**

John P. Moore & Dennis R. Burton

*Nature Medicine* August (2004)

● **Paradise lost & paradigm found**

Robert I. Lehrer

*Nature Immunology* August (2004)

● **Out of Thailand, into Africa**

Julie Clayton

*Nature* 08 July (2004)

As part of a series of News

Features written to coincide with

the XVth International AIDS

Conference in Bangkok, Julie

Clayton of *Nature* talks to Krisana

Kraisintu, the former director of

the Research and Development

Institute of Thailand's

Government Pharmaceutical

Organization (GPO), who is now

leading the drive to get generic

versions of branded anti-HIV

drugs into sub-saharan Africa.

▼ **Correlates of immune**

protection in HIV-1 infection: what

we know, what we don't know,

what we should know

Giuseppe Pantaleo &

Richard A. Koup

*Nature Medicine* August (2004)

Defining the immune correlates of

protection during vaccination and

natural infection has become a

key step in vaccine development.

In this excellent Perspective,

Pantaleo and Koup emphasize

the importance of determining

the correlates of protection for

individual HIV vaccines during

Phase III clinical trials.

